Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhythm PharmaceuticalsRYTM +0.59%57 Cash-to-Debt is 89.87 as of Jun. 2026, which is 18% below its 10-year median of 109.96. GuruFocus rates RYTM with a GF Score™ of 57/100 and a GF Value™ of $120.91 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,355 Biotechnology companies, Rhythm Pharmaceuticals ranks better than 75.5% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Rhythm Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 89.87.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Rhythm Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Rhythm Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
RYTM'
s Cash-to-Debt Range Over the Past 10 Years
Min: 44.28 Med: 109.96 Max: No Debt
Current: 89.87
During the past 11 years, Rhythm Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 44.28. And the median was 109.96.
RYTM's Cash-to-Debt is ranked better than 75.5% of 1355
companies
in the Biotechnology industry
Industry Median: 7.29
vs RYTM: 89.87
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Rhythm Pharmaceuticals Cash-to-Debt Related Terms
Rhythm Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Rhythm Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (RYTM) has a Cash-to-Debt of 89.87 as of Jun. 2026. This is 18% below median its historical median of 109.96. Over the past decade, Rhythm Pharmaceuticals' Cash-to-Debt has ranged from 44.28 to 10,000.00. According to the industry distribution chart, Rhythm Pharmaceuticals ranks #332 out of 1355 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Rhythm Pharmaceuticals' Cash-to-Debt too high?
Rhythm Pharmaceuticals' current Cash-to-Debt of 89.87 is 18% below median its 10-year median of 109.96. Over the past 10 years, this metric has ranged from a low of 44.28 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.29. Rhythm Pharmaceuticals' value of 89.87 is 1132.8% above this industry median. Based on the distribution chart, Rhythm Pharmaceuticals ranks #332 out of 1355 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rhythm Pharmaceuticals has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Cash-to-Debt compare to MIRM and COGT?
According to the Biotechnology industry distribution chart, Rhythm Pharmaceuticals ranks #332 out of 1355 companies for Cash-to-Debt. This places Rhythm Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.29. Rhythm Pharmaceuticals' value of 89.87 is 1132.8% above this benchmark. Historically, Rhythm Pharmaceuticals' own Cash-to-Debt has ranged from 44.28 to 10,000.00 over the past decade. While the company's 10-year median is 109.96 vs. the industry median of 7.29, Rhythm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.29, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Pharmaceuticals's current Cash-to-Debt of 89.87 is 1132.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Pharmaceuticals's current Cash-to-Debt is 89.87, which is 18% below median its own 10-year median of 109.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (RYTM) is currently considered Fairly Valued. The stock's GF Value™ is $120.91, compared to a current price of $112.58 — trading 6.9% below its estimated fair value. The current Cash-to-Debt is 89.87, which is 18% below median its 10-year median of 109.96 and 1132.8% above the Biotechnology industry median of 7.29. Rhythm Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Rhythm Pharmaceuticals (RYTM), the current Cash-to-Debt is 89.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued.
The current stock price of $112.58 is trading 6.9% below its estimated GF Value™ of $120.91.
GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.
Key valuation signals for RYTM:
Cash-to-Debt: 89.87 (18% below median its 10-year median of 109.96)
GF Value™: $120.91 vs. price of $112.58 (6.9% below fair value)
Industry Position: 1132.8% above the Biotechnology median (#332 of 1355)
No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
57GF Score
Get the complete analysis for RYTM
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYTM has been successfully added to your 
